Neoadjuvant FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: A phase II multicentre randomised controlled trial (PRODIGE 22)

Type de document :
Communication dans un congrès
the 42nd ESMO Congress (ESMO 2017), Sep 2017, Madrid, Spain. Annals of Oncology, Volume 28, Issue suppl_5, 1 September 2017, 28 (suppl_5), pp.476O, 2017, Abstract Book of the 42nd ESMO Congress (ESMO 2017) 8–12 September 2017, Madrid, Spain. 〈https://academic.oup.com/annonc/article/28/suppl_5/mdx393.003/4109775/476ONeoadjuvant-FOLFOX-4-versus-FOLFOX-4-plus〉. 〈10.1093/annonc/mdx393.003〉
Liste complète des métadonnées

https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01632311
Contributeur : Lnc - Université de Bourgogne <>
Soumis le : vendredi 10 novembre 2017 - 08:57:09
Dernière modification le : mercredi 20 juin 2018 - 11:56:11

Lien texte intégral

Identifiants

Collections

Citation

M. Karoui, A. Rullier, C. Mariette, E. Maillard, A. Bardier, et al.. Neoadjuvant FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: A phase II multicentre randomised controlled trial (PRODIGE 22). the 42nd ESMO Congress (ESMO 2017), Sep 2017, Madrid, Spain. Annals of Oncology, Volume 28, Issue suppl_5, 1 September 2017, 28 (suppl_5), pp.476O, 2017, Abstract Book of the 42nd ESMO Congress (ESMO 2017) 8–12 September 2017, Madrid, Spain. 〈https://academic.oup.com/annonc/article/28/suppl_5/mdx393.003/4109775/476ONeoadjuvant-FOLFOX-4-versus-FOLFOX-4-plus〉. 〈10.1093/annonc/mdx393.003〉. 〈hal-01632311〉

Partager

Métriques

Consultations de la notice

40